AGENDA DAY 1

 

Microbiome World Congress USA Day 1 2017

8:50 Chairperson’s Opening Remarks

TURNING RESEARCH INTO VIABLE THERAPEUTICS

09:00

Keynote Address: The new paradigm of treatment: Understanding the relationship between ecology and medicine in unlocking the potential of the microbiome

  • What is the current state of the field and how have new techniques in molecular biology enabled us to probe the microbiome and better understand its diversity and biological significance?
  • When dealing with living organisms- How does microbial ecology differ from classical drug therapies, and classical medical statistics?
  • What areas have we seen greatest progress and how do we avoid overselling microbiome potential and current state before we have solid evidence of translational capacity?
Scientific
09:40

Presentation: Re-assessing ethical issues in Microbiome research and medicine

  • What implications does Microbiome Research have on our social and legal systems?
  • Studies to advance personalized medicine will require broad public participation to provide sufficient material for biobanks and sample banks rather than a small sample of people with a target condition. 
  • How does this change the focus from the individual to community solidarity?
10:00

10:00 Speed Networking

10:20 Networking coffee break

CLINICAL TRIAL DESIGN, DATA AND PATIENT RECRUITMENT

Paul Carlson
11:00

FDA update: points to consider in when developing Microbiome treatments

  • Challenges in developing microbial treatments
  • Regulatory implications of C. Difficile- microbiome- Host interactions.
  • Understanding current guidelines for living biological samples.
Philip John Brooks
11:20

Presentation: Opportunities for microbiome research at the National Center for Advancing Translational Sciences (NCATS)

  • NCATS programs and funding opportunities for translational microbiome research.
  • What can we learn from proper design of small clinical trials?
Scientific
11:40

Presentation: The great potential and limitations of the mouse model

  • With mouse models being standard models why do we often see such varying results?
  • What microbiome communities are essential to lab mice?
  • Can cohabiting mice with common mice offer stronger research subjects that better replicate the human immune system?
Rodolphe Clerval, Chief Business Officer and Vice President of U.S. Operations, Enterome Bioscience

12:00 ROUNDTABLES

Roundtable 1: Mouse Models: The great potential and limitations of the mouse model

Roundtable 2: Skin microbiome: How do you develop various carbohydrate-polymer conjugates as selective fermentation inducers (SFIs) for editing skin microbiome?

Roundtable 5: Microbiome of the built environment: from research to application

Roundtable 6: Sponsorship Available

If you are interested in sponsoring the moderation of a roundtable contact Salvatore Manzo at +1 646 619 1798 or salvatore.manzo@terrapinn.com

12:40 LUNCH

DRUG DEVELOPMENT- BIOMARKER

Commercial
14:00

Panel: Cutting through the confusion of bioinformatics

  • Why do our models seem to break down when ecology meets the worlds of statistics and medicine?
  • How do we continue to identify the stable sub communities?
  • What bacterial interactions can we look to outside of our immediate field?
Moderator: Zachary Kurtz, Scientist, Lodo Therapeutics
Jason Norman, Senior Scientist, Vedanta Biosciences Inc
Hadley King, Staff Scientist, Mazumder Lab, School of Public Health and Health Services The George Washington University
Glen Satten, Senior Statistician, Center for Disease Control & Prevention
Commercial
14:40

Presentation: Developments of Targeted Therapy via Microbiome Community

  • The level of uniqueness in the microbiome make up means far more
  • How can we enhance sampling protocols with high quality metagenomic data?
  • How in depth must we go to identify key bacteria of interest?
  • With current treatments having wide ranging responses in patients- How personalized does each treatment need to be?
Scientific
14:50

Sponsored case study

DRUG DEVELOPMENT- DIAGNOSTIC VALIDATION

Commercial
15:00

Personalized nutrition for the microbiome

  • With microbiome and nutrition becoming more synergistic how close are we to moving prediction and prevention with dietary changes?
  • Looking at current data- How can we interpret the current state of individualized microbiome responses to various foods and healthy and diseased states?
  • What does this mean for the future of food and for the treatment landscape?
Suzanne Devkota, Assistant Professor Director Microbiome Research, Cedars Sinai Medical Center
Commercial
15:20

Presentation: The elite Athlete microbiome - what makes top athletes so unique?

  • How can we utilize next-generation sequencing to understand what makes elite athletes unique?
  • What changes are we seeing pre and post sport activity?
  • What does this mean in the next generation of athletes?
  • Are we seeing key markers for endurance, fatigue and recovery?
  • How can this be used to aid the wider population?
Jon Scheiman, Co-Founder, CEO, FitBiomics
Commercial
15:40

Presentation: Harnessing nature to help farmers sustainably feed the planet

  • How do we increase agricultural activity while not relying on technology of the high yields gains of the past?
  • What is being done to isolate the endophytes of various plants and how can this improve drought resistance, nutrient absorption, etc?
  • What real-life examples have we seen of the benefits of these enhanced food and crops?
Barry Goldman, Vice President, Discovery, Indigo Agriculture
Scientific
15:50

Presentation: Utilizing genetically engineered probiotics to treat disease

  • How can we use genetically engineered probiotics to treat disease?
  • What aspects of drug development are unique to synbiotics?
Marja Puurunen, Assoc. Medical Director, Synlogic Therapeutics
Commercial
15:50

Sponsored case study

16:00 Networking coffee break

Closing keynotes

Sloan Devlin
16:40

Keynote: A chemical understanding of the Gut Microbiome

  • Uncovering how and why bacteria metabolize bile acids?
  • How do these bile acids influence biological processes?
  • How can we make use of this to better monitor and alter bacterial metabolism in vivo?
Sloan Devlin, Harvard Medical School
Nikola Trbovic
17:00

Keynote:  A large pharma perspective on the microbiome

  • How does large pharma evaluate opportunities in the microbiome?
  • What developments in the field are we monitoring most closely?
  • What capabilities does large pharma consider most valuable in biotech partners?

17:20 Closing Remarks

17:30 Drinks Reception

last published: 06/Nov/17 14:55 GMT